<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03278691</url>
  </required_header>
  <id_info>
    <org_study_id>IRB # 1072359</org_study_id>
    <nct_id>NCT03278691</nct_id>
  </id_info>
  <brief_title>Ketorolac on Posterior Thoracolumbar Spinal Fusions</brief_title>
  <official_title>The Effect of Ketorolac on Posterior Thoracolumbar Spinal Fusions: a Prospective Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ascension South East Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ascension South East Michigan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine is low-dose ketorolac use in the early post-operative period (within 48 hours)&#xD;
      provides adequate analgesia without long term adverse effect on spinal fusion rates when&#xD;
      compared to post-operative analgesia without the use of NSAIDs.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 3, 2017</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fusion Construct X-Ray</measure>
    <time_frame>6 months postoperatively</time_frame>
    <description>Each fusion level will be evaluated individually and as part of the complete fusion construct. Fusion will be evaluated by blinded independent neuroradiologists using XR.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fusion Construct X-Ray</measure>
    <time_frame>12 months postoperatively</time_frame>
    <description>Each fusion level will be evaluated individually and as part of the complete fusion construct. Fusion will be evaluated by blinded independent neuroradiologists using XR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale (VAS) for pain</measure>
    <time_frame>Every 8 hours x 48 hours postoperatively</time_frame>
    <description>Patient will be given the VAS on the source document in order to draw on the scale&#xD;
Blinded investigators</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Stay (LOS)</measure>
    <time_frame>12 months postoperatively</time_frame>
    <description>-Measured in days (24 hours)&#xD;
â€¢ Automatic data capture on discharge by the hospital EMR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life - long term</measure>
    <time_frame>12 months postoperatively</time_frame>
    <description>Short Form (SF) 12&#xD;
We will administer validated scales, Short form (SF)12&#xD;
Face-to -face interview during clinic visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morphine equivalent doses</measure>
    <time_frame>12 months postoperatively</time_frame>
    <description>-Non-study narcotics taken by patients on the floor are converted to morphine equivalent doses&#xD;
Morphine equivalent doses are compared between the two groups daily for the first 48h&#xD;
Data extracted from hospital EMR on discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications/Adverse events</measure>
    <time_frame>12 months postoperatively</time_frame>
    <description>-Ketorolac-related short term in-hospital complications: GI ulceration and bleeding, GI perforation, PO bleeding, acute renal failure, anaphylactic/anaphylactoid reactions, liver failure&#xD;
Collected by investigators daily during round&#xD;
Document on the source document</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life - long term</measure>
    <time_frame>12 months postoperatively</time_frame>
    <description>Oswestry Disability Index (ODI)&#xD;
We will administer validated scales (ODI)&#xD;
Face-to -face interview during clinic visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life - long term</measure>
    <time_frame>12 months postoperatively</time_frame>
    <description>We will administer validated scales, Visual Analog Scale (VAS)&#xD;
Face-to -face interview during clinic visit</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Thoracolumbar Spinal Fusions</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Placebo Saline 1 ml IV Q6H</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketorolac 15 mg (15mg/ml) IV Q6H</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>1 ml saline IV Q6H</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac</intervention_name>
    <description>15 mg (15 mg/ml) IV Q6H</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Over 18 years of age&#xD;
&#xD;
          -  Elective thoracolumbar posterior lumbar instrumented interbody fusion&#xD;
&#xD;
          -  Minimally invasive spine surgery (MIS)&#xD;
&#xD;
          -  3 or fewer levels&#xD;
&#xD;
          -  Bone Morphogenetic Protein (BMP) use in interbody fusion (1.05mg/level or less)&#xD;
&#xD;
          -  Consent to study participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active tobacco smoker or history of tobacco smoking in the past 6 weeks&#xD;
&#xD;
          -  Previous history of surgery at operative level(s)&#xD;
&#xD;
          -  History of chronic inflammatory/rheumatological condition&#xD;
&#xD;
          -  History of systemic steroid use in the past 3 months&#xD;
&#xD;
          -  Auto/Workers' compensation patients&#xD;
&#xD;
          -  Traumatic pathology at the operative levels&#xD;
&#xD;
          -  Infection at the operative levels&#xD;
&#xD;
          -  Tumor at the operative levels&#xD;
&#xD;
          -  Major psychiatric illness as diagnosed by psychiatrists and on major anti-&#xD;
             psychotic/depressants&#xD;
&#xD;
          -  Patients on chemotherapeutic agents in the last 6 months&#xD;
&#xD;
          -  Patients who has a history of allergy to Ketorolac&#xD;
&#xD;
          -  Patients with a history of chemical addiction requiring professional rehabilitation&#xD;
             and/or assistance&#xD;
&#xD;
          -  Patients with current creatinine &gt; 1.5mg/dl&#xD;
&#xD;
          -  Patients with history of coagulopathy&#xD;
&#xD;
          -  Patients with history of hepatic impairment&#xD;
&#xD;
          -  Patients with uncontrolled cardiovascular disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chad Claus, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Providence-Providence Park Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chad Claus, DO</last_name>
    <phone>702-493-7856</phone>
    <email>chadfclaus@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Providence-Providence Park, Southfield</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48075</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frances Williams, MBA, MPH</last_name>
      <phone>248-849-5326</phone>
      <email>Frances.Williams3@ascension.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 24, 2017</study_first_submitted>
  <study_first_submitted_qc>September 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2017</study_first_posted>
  <last_update_submitted>January 22, 2021</last_update_submitted>
  <last_update_submitted_qc>January 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

